Drug intelligence / Profile preview

MALT1 inhibitor

Development stage: Preclinical
Lead developer: C4X Discovery Holdings
Modality: Small Molecules
Administration: Oral

Overview

MALT1 inhibitor (C4X Discovery) is a small-molecule inhibitor of Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) currently in development by C4X Discovery for the treatment of immuno-inflammatory diseases. MALT1 is a paracaspase that functions as a key signaling component within the CBM (CARMA1-BCL10-MALT1) complex, which is essential for the activation of the NF-κB pathway in response to antigen receptor stimulation in T and B cells. By inhibiting MALT1, the drug aims to modulate the immune response and reduce the production of pro-inflammatory cytokines, providing a targeted approach for chronic inflammatory conditions.

Targets

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)

Beyond the preview

Go deeper on MALT1 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MALT1 inhibitor.

Explore the full profile